Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer

Minetta C. Liu, Peter G. Shields, Robert D. Warren, Philip Cohen, Mary Wilkinson, Yvonne L. Ottaviano, Suman B. Rao, Jennifer Eng-Wong, Francoise Seillier-Moiseiwitsch, Anne Michelle Noone, Claudine Isaacs

Research output: Contribution to journalArticle

228 Scopus citations

Abstract

Purpose: Five or more circulating tumor cells (CTCs) per 7.5 mL of blood predicts for poorer progression-free survival (PFS) in patients with metastatic breast cancer (MBC). We conducted a prospective study to demonstrate that CTC results correlate strongly with radiographic disease progression at the time of and in advance of imaging. Patients and Methods: Serial CTC levels were obtained in patients starting a new treatment regimen for progressive, radiographically measurable MBC. Peripheral blood was collected for CTC enumeration at baseline and at 3- to 4-week intervals. Clinical outcomes were based on radiographic studies performed in 9- to 12-week intervals. Results: Sixty-eight patients were evaluable for the CTC-imaging correlations, and 74 patients were evaluable for the PFS analysis. Median follow-up was 13.3 months. A statistically significant correlation was demonstrated between CTC levels and radiographic disease progression in patients receiving chemotherapy or endocrine therapy. This correlation applied to CTC results obtained at the time of imaging (odds ratio [OR], 6.3), 3 to 5 weeks before imaging (OR, 3.1), and 7 to 9 weeks before imaging (OR, 4.9). Results from analyses stratified by type of therapy remained statistically significant. Shorter PFS was observed for patients with five or more CTCs at 3 to 5 weeks and at 7 to 9 weeks after the start of treatment. Conclusion: We provide, to our knowledge, the first evidence of a strong correlation between CTC results and radiographic disease progression in patients receiving chemotherapy or endocrine therapy for MBC. These findings support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC.

Original languageEnglish (US)
Pages (from-to)5153-5159
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number31
DOIs
StatePublished - Nov 1 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Liu, M. C., Shields, P. G., Warren, R. D., Cohen, P., Wilkinson, M., Ottaviano, Y. L., Rao, S. B., Eng-Wong, J., Seillier-Moiseiwitsch, F., Noone, A. M., & Isaacs, C. (2009). Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer. Journal of Clinical Oncology, 27(31), 5153-5159. https://doi.org/10.1200/JCO.2008.20.6664